VECTIBIX PLUS OXALIPLATIN-BASED ADJUVANT TREATMENT OF RECTAL CANCER
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Primary objectives: To assess the feasibility and preliminary efficacy of adding standard dose panitumumab to standard dose adjuvant FOLFOX4 chemotherapy in patients with resected rectal cancer Primary endpoints: Incidence of unacceptable toxicity (defined as grade 4 adverse event or any toxicity leading to discontinuation of therapy) of the combination of FOLFOX4-panitumumab, as per NCI-CTC guidelines, version 3
创建时间：
2010-09-15
